Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (under the brand names Ozempic and Rybelsus), chronic weight management (Wegovy), and cardiovascular risk reduction in specific populations
A physician-led medical weight loss program may help patients discuss symptom changes in the context of their broader health and treatment progress instead of treating every side effect as an isolated problem
In these studies, patients experienced elevated rates of adverse reactions, including weight loss, decreased BMI, decreased appetite, insomnia, infections (upper respiratory and nasopharyngitis), irritability, and affect lability
Depression linked to semaglutide is quite rare but has been reported
Take home message Wegovy can be taken after gastric sleeve surgery, and the growing evidence suggests its both safe and effective for managing weight regain